[What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Rosolová H
  • Source:
    Vnitrni lekarstvi [Vnitr Lek] 2015 Nov; Vol. 61 (11), pp. 971-5.
  • Publication Type:
    Journal Article; Review
  • Language:
    Czech
  • Additional Information
    • Transliterated Title:
      Co přináší přehledný článek o důkazech redukce makrovaskulárního rizika u pacientů s aterogenní dyslipidemií? Zpráva o konsenzu expertů o významu kombinované terapie fenofibrátem a statinem.
    • Source:
      Publisher: Ambit Media Country of Publication: Czech Republic NLM ID: 0413602 Publication Model: Print Cited Medium: Print ISSN: 0042-773X (Print) Linking ISSN: 0042773X NLM ISO Abbreviation: Vnitr Lek Subsets: MEDLINE
    • Publication Information:
      Publication: 2010- : Brno : Ambit Media
      Original Publication: 1973-<1994> : Praha : Avicenum
    • Subject Terms:
      Atherosclerosis/*drug therapy ; Diabetes Mellitus, Type 2/*drug therapy ; Dyslipidemias/*drug therapy ; Fenofibrate/*therapeutic use ; Lipids/*blood; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Dyslipidemias/blood ; Dyslipidemias/complications ; Humans ; Hypolipidemic Agents/therapeutic use
    • Abstract:
      A meeting of European experts in cardiovascular (CV) disease and lipids was convened in Paris, November 2014, where an important problem of preventive cardiology--residual vascular risk done by atherogenic dyslipidemia (AD)--was discussed. On the basis of discussion have the experts summarised a consensus concerning AD, its CV risk and up to date evidence of combined therapy with statin and fenofibrate on CV risk. Atherogenic dyslipidemia should be the secondary aim of dyslipidemia treatment, because it is a reason of residual vascular risk. Non-HDL-cholesterol should be the secondary target of AD treatment, which is a most unexpensive and easiest marker of residual vascular risk. Combined therapy with statin and fenofibrate is safe, well tolerated and reduces plasma atherogenity and CV events in patients with AD and high CV risk, type 2 diabetes or metabolic syndrome.
    • Accession Number:
      0 (Hypolipidemic Agents)
      0 (Lipids)
      U202363UOS (Fenofibrate)
    • Publication Date:
      Date Created: 20151215 Date Completed: 20160324 Latest Revision: 20181202
    • Publication Date:
      20250114
    • Accession Number:
      26652786